Thermo Fisher: A High-Quality Life Science Platform Positioned For Growth

Thermo Fisher shares have declined ~20% YTD, presenting an attractive long-term entry point given its resilient business model and broad platform. TMO's diversified segments, recurring consumables revenue, and strong M&A track record underpin its competitive advantage across the life sciences value chain. Despite cautious FY26 guidance (4–6% revenue growth), TMO's EBITDA margin has normalized, and long-term demand drivers remain robust.

Seeking Alpha • Mar 18, 2026

Is This the Right Time to Hold Thermo Fisher Stock in Your Portfolio?

TMO's acquisitions and resilient pharma, biotech and diagnostics demand support growth, but currency swings and fierce competition remain risks.

Zacks Investment Research • Mar 6, 2026

Thermo Fisher Scientific Opens Bay Area Cryo-EM Drug Discovery Center to Accelerate Breakthrough Therapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of its Cryo-Electron Microscopy (cryo-EM) Drug Discovery Center (CDDC) in South San Francisco. The new center provides pharmaceutical and biotechnology innovators with immersive, hands-on access to advanced cryo-EM technologies designed to accelerate structural insights and the development of life-saving therapies. Accelerating Drug Discovery with Cryo-EM The.

Business Wire • Mar 5, 2026

Thermo Fisher Scientific Inc. (TMO) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

Thermo Fisher Scientific Inc. (TMO) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript

Seeking Alpha • Mar 3, 2026

Baron Health Care Fund Q4 2025 Recent Activity

During the quarter, Baron Health Care Fund added seven new positions and exited ten positions, bringing the number of positions in the Fund to 43. We bought shares of Arcutis Biotherapeutics, Inc., a biotechnology company that sells Zoryve cream and foam for the treatment of autoimmune dermatologic conditions. We sold Cidara Therapeutics, Inc. after the company announced it was being acquired by Merck for a substantial premium.

Seeking Alpha • Mar 3, 2026

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1. Invasive fungal infections are an increasing challenge for healthcare systems w.

Business Wire • Mar 2, 2026

Thermo Fisher Scientific: Recovery In Life Sciences Solutions

Thermo Fisher Scientific is reiterated as a 'buy' with a fair value estimate of $619 per share, reflecting confidence in its recovery and strategic positioning. TMO's acquisition of Clario Holdings for $8.875 billion is expected to enhance recurring revenue, accelerate organic growth, and support future AI-driven clinical trial solutions. Management guides for 3%-4% organic revenue growth and 6%-8% adjusted EPS growth in FY26, underpinned by improving biotech funding and market sentiment.

Seeking Alpha • Mar 2, 2026

Top 15 High-Growth Dividend Stocks For March 2026

The March 2026 Top 15 dividend growth stocks list targets high-quality, undervalued companies with a projected 21.28% long-term CAGR and 1.13% average yield. Pure Quality and Value-focused stock selection strategies outperformed the original blended approach in February, though all variants posted negative returns for the month. Since inception, the watch list has underperformed SPY and VIG, with an 8.82% annualized return versus 14.59% and 12.34% respectively, but surfaced several high-return opportunities.

Seeking Alpha • Mar 2, 2026

Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection. For transplant recipients, finding the right tacrolimus dose as early as possible can be life-changing. If the dose is too low, the body may.

Business Wire • Feb 26, 2026

Thermo Fisher Scientific Increases Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40.

Business Wire • Feb 25, 2026